In last trading session, Legend Biotech Corp ADR (NASDAQ:LEGN) saw 1.89 million shares changing hands with its beta currently measuring 0.09. Company’s recent per share price level of $40.95 trading at -$0.44 or -1.06% at ring of the bell on the day assigns it a market valuation of $7.50B. That closing price of LEGN’s stock is at a discount of -71.26% from its 52-week high price of $70.13 and is indicating a premium of 5.74% from its 52-week low price of $38.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.36 million shares which gives us an average trading volume of 1.06 million if we extend that period to 3-months.
For Legend Biotech Corp ADR (LEGN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 11 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.42 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Upright in the red during last session for losing -1.06%, in the last five days LEGN remained trading in the red while hitting it’s week-highest on Tuesday, 11/05/24 when the stock touched $40.95 price level, adding 14.31% to its value on the day. Legend Biotech Corp ADR’s shares saw a change of -31.94% in year-to-date performance and have moved -9.04% in past 5-day. Legend Biotech Corp ADR (NASDAQ:LEGN) showed a performance of -16.15% in past 30-days. Number of shares sold short was 11.95 million shares which calculate 11.67 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 86 to the stock, which implies a rise of 52.38% to its current value. Analysts have been projecting 60 as a low price target for the stock while placing it at a high target of 94. It follows that stock’s current price would drop -46.52% in reaching the projected high whereas dropping to the targeted low would mean a loss of -46.52% for stock’s current value.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Statistics highlight that Legend Biotech Corp ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -10.04% of value to its shares in past 6 months, showing an annual growth rate of -0.68% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 105.90% from the last financial year’s standing.
14 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 143.87M for the same. And 14 analysts are in estimates of company making revenue of 176.9M in the next quarter. Company posted 96.01M and 79.46M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -168.48% during past 5 years.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
FMR LLC is the top institutional holder at LEGN for having 17.62 million shares of worth $780.46 million. And as of 2024-06-30, it was holding 9.6819 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 11.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3126 of outstanding shares, having a total worth of $508.86 million.
